Through advanced genetic sequencing, chemotherapy and the expertise of a large medical team, doctors were able to identify a treatment approach tailored to Hadley's unique tumor. With the help of precision medicine and months of treatment, Hadley began defying expectations. Read more: https://www.cbsnews.com/colorado/news/childhood-brain-stem-cancer-survivor-colorado-girl/

This agent is more like a lock-and-key approach aimed at the biology driving the leukemia itself. The hope is not just survival, but a better life after survival, because for children, beating cancer isn't the end of the story. Read more: https://www.cbsnews.com/atlanta/news/emory-university-team-explores-promising-new-therapy-for-childhood-leukemia-with-fewer-toxic-effects/

A Children’s Hospital Los Angeles study has shed new light on the molecular drivers of FOXR2-activated CNS neuroblastoma, an extremely rare pediatric brain tumor that can be difficult to diagnose without advanced testing. Read more: https://www.newswise.com/articles/children-s-hospital-los-angeles-researchers-uncover-genetic-clues-to-rare-childhood-brain-tumor

A cancer researcher at the University of Houston is reporting what makes malignant soft tissue cancer grow in children, identifying key mechanisms and molecular targets to prevent tumor progression in patients in future therapies of the fatal rhabdomyosarcoma. Read more: https://www.uh.edu/news-events/stories/2026/june/06092026-kumar-soft-tissue-rhabdomyosarcoma.php

Forty years of studies find higher cancer risks among children exposed during pregnancy and early life to pesticides used on farms, lawns, gardens, and pets. Read more: https://usrtk.org/healthwire/pesticide-use-linked-to-childhood-leukemia-brain-tumors/

John Bushweller, PhD, Professor of Molecular Physiology and Biological Physics at UVA and co-leader of the Cancer Biology Program at UVA Comprehensive Cancer Center, is collaborating with C-Further, an international consortium dedicated to advancing new therapies for childhood cancers, to develop a new treatment option that targets a transcription factor that fuels Ewing Sarcoma. The goal is a new drug that could offer better outcomes with less toxicity. Read more: https://ww

Following induction treatment for high-risk neuroblastoma, more than half of children experience cisplatin-induced hearing loss (CIHL), according to research published in JCO Clinical Advances. Read more: https://www.cancertherapyadvisor.com/news/cisplatin-hearing-loss-pediatric-high-risk-neuroblastoma/

Nagourney Cancer Institute and Metabolomycs with the FibroFighters Foundation showed fibrolamellar cancers appear to arise through changes in cellular metabolism. Read more: https://finance.yahoo.com/sectors/healthcare/articles/breakthrough-highly-lethal-childhood-cancer-140000323.html

"The biology has been pointing in this direction for a decade. The regulatory architecture is in place. The incentives exist. What happens in the next generation of molecularly targeted oncology programs will depend on whether protocol teams treat that nine-year-old’s NTRK fusion as a scheduling problem for post-approval — or as the enrollment criterion she was always supposed to be." Read more: https://www.clinicaltrialvanguard.com/opinion/pediatric-oncology-keeps-getting-tr

Healthy lifestyles can reduce the risk of cardiovascular disease and other complications in childhood cancer survivors. These are the findings of two new international studies. Read more: https://www.eurekalert.org/news-releases/1130093